Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 8/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
| ▸ | QDPR | P09417 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16801569 | 0.92 | SLC6A4 (0.71) | SLC6A4HTR6 | |
| SCHEMBL16801502 | 0.86 | MAPT (0.59) | SLC6A4MAPTHTR6LMNAPOLB | |
| SCHEMBL16801678 | 0.84 | SLC6A4 (0.56) | SLC6A4MAPTHTR6LMNAPOLB | |
| SCHEMBL6345407 | 0.82 | SLC6A4 (0.69) | SLC6A4HTR6 | |
| SCHEMBL18324802 | 0.81 | MAPT (0.52) | MAPTLMNAPOLBTP53TDO2 | |
| SCHEMBL11864713 | 0.81 | LMNA (0.66) | SLC6A4MAPTHTR6LMNAPOLB | |
| Oxalic Acid SCHEMBL7865005 | 0.81 | KDM4E (0.59) | SLC6A4HTR6LMNA | |
| SCHEMBL18324766 | 0.79 | SLC6A4 (0.49) | SLC6A4MAPTLMNAPOLBTDO2 | |
| SCHEMBL16801553 | 0.79 | SLC6A4 (0.67) | SLC6A4MAPTLMNA | |
| SCHEMBL4881377 | 0.79 | SLC6A4 (0.63) | SLC6A4HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3082802-B1 | TRYPTOPHAN-2,3-DIOXYGENASE (TDO) AND/OR INDOLAMINE-2,3-DIOXYGENASE (IDO) INHIBITORS AND THEIR USE | IOMET PHARMA LTD (GB) | 2020-02-26 | — | — | EP | disclosed |
| US-9931347-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9931347-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20160367564-A1 | Pharmaceutical Compound | IOMET PHARMA LTD. (GB) | 2016-12-22 | — | — | US | disclosed |
| US-20160367564-A1 | Pharmaceutical Compound | IOMET PHARMA LTD. (GB) | 2016-12-22 | — | — | US | disclosed |
| WO-2015082499-A2 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD (GB) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367564-A1 | Pharmaceutical Compound | TDO2, IDO1, IDO2 | SLC6A4 73/4885MAPT 2964/4885HTR6 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.